---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032514"
form_type: "8-K"
ticker: null
cik: "0001559356"
company_name: "Biostax Corp."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:02:57.365208+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CEO Kelly Wilson and President Robert Wilson resign; Noreen Griffin appointed CEO

## Summary
- Robert Wilson resigned as President on July 25, 2023; no dispute cited.
- Kelly Wilson resigned as CEO on July 25, 2023; appointed President same day.
- Noreen Griffin named CEO under consulting agreement; monthly fee $20,834, deferred until $1M funding threshold with 8.5% interest.
- Griffin, age 70, previously VP of company and former CEO; family ties to both Wilson executives.
- Kelly Wilson's compensation continues under prior consulting agreement dated November 1, 2022.

## SEC filing metadata
- accession: 0001493152-23-032514
- form_type: 8-K
- cik: 0001559356
- company_name: Biostax Corp.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032514
- JSON: https://secwatch.observer/filing/0001493152-23-032514.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032514.txt

## Key facts
- Executive change
  Robert Wilson resigned as President at Biostax Corp..
  - Action: resigned
  - Role: President
  source text: On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm
- Executive change
  Kelly Wilson resigned as Chief Executive Officer at Biostax Corp..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Company, delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm
- Executive change
  Noreen Griffin was appointed as Chief Executive Officer at Biostax Corp..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.